Christopher Dumont
Overview
Christopher Dumont is a counsel in Crowell & Moring’s Brussels office and is a member of the Intellectual Property Group.
Christopher advises and assists clients on a wide range of IP/IT law matters, both contentious and non-contentious, focusing on life sciences litigation. He has extensive experience advising and litigating complex trademark and patent disputes such as SPCs, SPC manufacturing waivers, and the Bolar exemption. He has also developed strong knowledge in advisory and litigation matters before European courts, regarding, among other things, data exclusivity and market protection issues related to pharmaceuticals.
Before joining Crowell as a senior associate in February 2022, Christopher worked for three and a half years at a leading Belgian law firm.
Career & Education
- Catholic University of Leuven, B.A., honours program, 2015
- Catholic University of Leuven, J.D., honours program, 2017
- Catholic University of Leuven, LL.M., intellectual property law, 2018
- Belgium
- European Court
- Dutch
- English
- French
Kristof Roox and Christopher Dumont are able to deliver within tight deadlines. They bring innovative ways to help customers, excellent collaboration within a group of customers. Clear when conveying information and summaries.
— Legal 500, 2024
Christopher's Insights
Client Alert | 2 min read | 03.12.26
The EU Pharma Package: Formal Adoption in Sight
The EU Pharma Package represents the most significant reform of EU pharmaceutical legislation in over two decades, setting the stage for a new era in medicine regulation. Introduced by the European Commission back in April 2023, the proposals are designed to promote innovation, strengthen medicine availability and affordability, reduce regulatory burdens, ensure a fair and competitive European pharmaceutical market, and modernize the EU's pharmaceutical framework. The EU Pharma Package will replace the more than twenty-year-old Directive 2001/83/EC and Regulation 726/2004, and incorporates the separate regulations on orphan and pediatric medicines, thereby bringing the entire regulatory framework up to date.
Publication | 02.03.26
Drowning in EU regulations? Five tips for surviving the deluge of new rules
Firm News | 7 min read | 01.09.26
Crowell & Moring Elects 15 New Partners, Promotes One to Senior Counsel and 26 to Counsel
Client Alert | 6 min read | 12.15.25
The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package
Representative Matters
- Assisting leading pharmaceutical companies in preliminary injunction proceedings regarding generic versions of blockbuster medicinal products.
- Assisting one of the largest tobacco companies in a multilayered cross-border trademark litigation against a spread-out network of infringers.
- Assisting a leading financial company in the development and maintenance of their trademark portfolio.
- Assisting a major Belgian book publisher in complex litigation and investigation by court-appointed expert concerning the publishing and audiovisual rights attached to a graphic character.
- Negotiating a global software license for a consortium of companies in the recycling industry.
- Assisting a European public-private partnership with the supply of data protection and related services.
Christopher's Insights
Client Alert | 2 min read | 03.12.26
The EU Pharma Package: Formal Adoption in Sight
The EU Pharma Package represents the most significant reform of EU pharmaceutical legislation in over two decades, setting the stage for a new era in medicine regulation. Introduced by the European Commission back in April 2023, the proposals are designed to promote innovation, strengthen medicine availability and affordability, reduce regulatory burdens, ensure a fair and competitive European pharmaceutical market, and modernize the EU's pharmaceutical framework. The EU Pharma Package will replace the more than twenty-year-old Directive 2001/83/EC and Regulation 726/2004, and incorporates the separate regulations on orphan and pediatric medicines, thereby bringing the entire regulatory framework up to date.
Publication | 02.03.26
Drowning in EU regulations? Five tips for surviving the deluge of new rules
Firm News | 7 min read | 01.09.26
Crowell & Moring Elects 15 New Partners, Promotes One to Senior Counsel and 26 to Counsel
Client Alert | 6 min read | 12.15.25
The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package
Recognition
IAM Patent 1000: Litigation and Transactions, Recommended, 2025
Christopher's Insights
Client Alert | 2 min read | 03.12.26
The EU Pharma Package: Formal Adoption in Sight
The EU Pharma Package represents the most significant reform of EU pharmaceutical legislation in over two decades, setting the stage for a new era in medicine regulation. Introduced by the European Commission back in April 2023, the proposals are designed to promote innovation, strengthen medicine availability and affordability, reduce regulatory burdens, ensure a fair and competitive European pharmaceutical market, and modernize the EU's pharmaceutical framework. The EU Pharma Package will replace the more than twenty-year-old Directive 2001/83/EC and Regulation 726/2004, and incorporates the separate regulations on orphan and pediatric medicines, thereby bringing the entire regulatory framework up to date.
Publication | 02.03.26
Drowning in EU regulations? Five tips for surviving the deluge of new rules
Firm News | 7 min read | 01.09.26
Crowell & Moring Elects 15 New Partners, Promotes One to Senior Counsel and 26 to Counsel
Client Alert | 6 min read | 12.15.25
The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package
Insights
Drowning in EU regulations? Five tips for surviving the deluge of new rules
|02.03.26
Life Sciences Intellectual Property Review (LSIPR)
Standing to litigate and effects on remedies
|01.01.20
ICIP 2020, Vol. 2, 317-359
"FRAND licensing", Young EPLaw Congress, Brussels
|04.28.25
Practices
- Intellectual Property — Brussels Practice
- Intellectual Property Litigation
- Dispute Resolution — Brussels Practice
- Intellectual Property
- Digital Advertising
- Technology, Media, and Telecommunications — Brussels Practice
- Brussels Practice
- Digital Health and Health Information Technology
- Life Sciences — Intellectual Property
- Life Sciences
- Life Sciences — Brussels Practice
Industries
Christopher's Insights
Client Alert | 2 min read | 03.12.26
The EU Pharma Package: Formal Adoption in Sight
The EU Pharma Package represents the most significant reform of EU pharmaceutical legislation in over two decades, setting the stage for a new era in medicine regulation. Introduced by the European Commission back in April 2023, the proposals are designed to promote innovation, strengthen medicine availability and affordability, reduce regulatory burdens, ensure a fair and competitive European pharmaceutical market, and modernize the EU's pharmaceutical framework. The EU Pharma Package will replace the more than twenty-year-old Directive 2001/83/EC and Regulation 726/2004, and incorporates the separate regulations on orphan and pediatric medicines, thereby bringing the entire regulatory framework up to date.
Publication | 02.03.26
Drowning in EU regulations? Five tips for surviving the deluge of new rules
Firm News | 7 min read | 01.09.26
Crowell & Moring Elects 15 New Partners, Promotes One to Senior Counsel and 26 to Counsel
Client Alert | 6 min read | 12.15.25
The New EU “Pharma Package:” EU Reaches Landmark Deal on Pharma Package
